Latest Pharma and Biotech News
Pharmaceutical
11 April 2025 The US Centers for Medicare & Medicaid Services (CMS) has announced action intended to preserve the core mission of the Medicaid program against a wider backdrop of wider cost-cutting under the regime of President Donald Trump.
Today's issue
Refine Search
Pharmaceutical
Deal-making news last week included US drug developer KalVista Pharma signing a licensing agreement with Kaken Pharma to market its investigational hereditary angioedema (HAE) drug sebetralstat in Japan. US biotech firm Cartesian Therapeutics released positive Phase III data on its Descartes-08 in myasthenia gravis. The US Appeal Court gave a favorable ruling on Indian drugmaker Sun pharmaceuticals’ alopecia drug Leqselvi. Also of note, the US Food and Drug Administration (FDA) last week approved Bristol Meyers Squibb’s checkpoint therapy Opdivo plus Yervoy. 13 April 2025
Biotechnology
US mRNA specialist Moderna has announced that the German Standing Committee on Vaccination (STIKO) has issued a recommendation for mRESVIA, the company’s RSV vaccine available in a pre-filled syringe (PFS). 11 April 2025
Pharmaceutical
Speculation about the US Administration’s views on the Pharmaceutical Benefits Scheme (PBS) has reconfirmed the sanctity of the PBS as the cornerstone of Australia’s healthcare system, the domestic pharma trade group stressed. 11 April 2025
Biotechnology
Johnson & Johnson has announced new data from an analysis modelling long-term progression free survival (PFS) in transplant eligible (TE) and transplant ineligible (TIE) newly diagnosed multiple myeloma (NDMM) patients given Darzalex (daratumumab)-subcutaneous (SC) therapy alongside bortezomib, lenalidomide and dexamethasone (VRd). 11 April 2025
Biotechnology
US biotech giant Amgen today announced a significant breakthrough with its global Phase III DeLLphi-304 clinical trial evaluating Imdelltra (tarlatamab-dlle). 11 April 2025
Pharmaceutical
The obesity drug market has experienced a seismic shift in recent years, with Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Mounjaro (tirzepatide) revolutionizing the way the condition is treated. 11 April 2025
Pharmaceutical
Indian drugmaker Sun Pharmaceutical shares were buzzing in trade on the last trading day of the week to April 11, rising as much as 5%. 11 April 2025
Pharmaceutical
The US Centers for Medicare & Medicaid Services (CMS) has announced action intended to preserve the core mission of the Medicaid program against a wider backdrop of wider cost-cutting under the regime of President Donald Trump. 11 April 2025
Pharmaceutical
US biopharma company Palatin Technologies is at risk of being removed from the NYSE American exchange after failing to meet minimum stockholders' equity requirements. 11 April 2025
Biotechnology
US biotech Oncolytics Biotech has entered into a funding agreement with institutional investor Alumni Capital, providing access to up to $20 million in equity financing over the next 15 months. 11 April 2025
Pharmaceutical
The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s Truqap (capivasertib) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer that has certain genetic mutations and has spread. 11 April 2025
Biotechnology
Australian biotech Opthea is cutting around two-thirds of its workforce, as the company moves to curb spending following the collapse of its lead program for age-related macular degeneration (AMD). 11 April 2025
Pharmaceutical
Swiss pharma giant Novartis has announced a planned $23 billion investment over five years in US-based infrastructure, ensuring all key Novartis medicines for US patients will be made in the USA. 11 April 2025
Pharmaceutical
US biotech Imbria Pharmaceuticals has raised $57.5 million in a series B financing round to fund a new mid-stage trial of its only pipeline drug, ninerafaxstat, for a form of heart muscle disease with limited treatment options. 11 April 2025
Biotechnology
Late Thursday, the US Food and Drug Administration revealed it is taking a ground-breaking step to advance public health by replacing animal testing in the development of monoclonal antibody (MAb) therapies and other drugs with more effective, human-relevant methods. 11 April 2025
Biotechnology
US biotech Atossa Therapeutics has entered into a research collaboration with China-backed Nona Biosciences, aiming to identify next-generation antibody therapies for breast cancer using Nona’s proprietary platform technology. 10 April 2025
Biotechnology
US clinical-stage biotech Imbria Pharmaceuticals, which is focused on cardiometabolic diseases with high unmet need, says it has closed a $57.5 million Seres B financing. 10 April 2025
Pharmaceutical
Pain is good. Or finding non-opioid ways to manage it is good, if Latigo Biotherapeutics’ $150 million March fundraise is anything to go by. 10 April 2025
Biotechnology
US biotech ImmunityBio has secured $75 million through a direct offering with a single institutional investor, according to a statement released Tuesday. 10 April 2025
All news
Pharmaceutical
Deal-making news last week included US drug developer KalVista Pharma signing a licensing agreement with Kaken Pharma to market its investigational hereditary angioedema (HAE) drug sebetralstat in Japan. US biotech firm Cartesian Therapeutics released positive Phase III data on its Descartes-08 in myasthenia gravis. The US Appeal Court gave a favorable ruling on Indian drugmaker Sun pharmaceuticals’ alopecia drug Leqselvi. Also of note, the US Food and Drug Administration (FDA) last week approved Bristol Meyers Squibb’s checkpoint therapy Opdivo plus Yervoy. 13 April 2025
Biotechnology
US mRNA specialist Moderna has announced that the German Standing Committee on Vaccination (STIKO) has issued a recommendation for mRESVIA, the company’s RSV vaccine available in a pre-filled syringe (PFS). 11 April 2025
Pharmaceutical
Speculation about the US Administration’s views on the Pharmaceutical Benefits Scheme (PBS) has reconfirmed the sanctity of the PBS as the cornerstone of Australia’s healthcare system, the domestic pharma trade group stressed. 11 April 2025
Biotechnology
Johnson & Johnson has announced new data from an analysis modelling long-term progression free survival (PFS) in transplant eligible (TE) and transplant ineligible (TIE) newly diagnosed multiple myeloma (NDMM) patients given Darzalex (daratumumab)-subcutaneous (SC) therapy alongside bortezomib, lenalidomide and dexamethasone (VRd). 11 April 2025
Biotechnology
US biotech giant Amgen today announced a significant breakthrough with its global Phase III DeLLphi-304 clinical trial evaluating Imdelltra (tarlatamab-dlle). 11 April 2025
Pharmaceutical
The obesity drug market has experienced a seismic shift in recent years, with Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Mounjaro (tirzepatide) revolutionizing the way the condition is treated. 11 April 2025
Pharmaceutical
Indian drugmaker Sun Pharmaceutical shares were buzzing in trade on the last trading day of the week to April 11, rising as much as 5%. 11 April 2025
Pharmaceutical
The US Centers for Medicare & Medicaid Services (CMS) has announced action intended to preserve the core mission of the Medicaid program against a wider backdrop of wider cost-cutting under the regime of President Donald Trump. 11 April 2025
Pharmaceutical
US biopharma company Palatin Technologies is at risk of being removed from the NYSE American exchange after failing to meet minimum stockholders' equity requirements. 11 April 2025
Biotechnology
US biotech Oncolytics Biotech has entered into a funding agreement with institutional investor Alumni Capital, providing access to up to $20 million in equity financing over the next 15 months. 11 April 2025
Pharmaceutical
The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s Truqap (capivasertib) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer that has certain genetic mutations and has spread. 11 April 2025
Biotechnology
Australian biotech Opthea is cutting around two-thirds of its workforce, as the company moves to curb spending following the collapse of its lead program for age-related macular degeneration (AMD). 11 April 2025
Pharmaceutical
Swiss pharma giant Novartis has announced a planned $23 billion investment over five years in US-based infrastructure, ensuring all key Novartis medicines for US patients will be made in the USA. 11 April 2025
Pharmaceutical
US biotech Imbria Pharmaceuticals has raised $57.5 million in a series B financing round to fund a new mid-stage trial of its only pipeline drug, ninerafaxstat, for a form of heart muscle disease with limited treatment options. 11 April 2025
Biotechnology
Late Thursday, the US Food and Drug Administration revealed it is taking a ground-breaking step to advance public health by replacing animal testing in the development of monoclonal antibody (MAb) therapies and other drugs with more effective, human-relevant methods. 11 April 2025
Biotechnology
US biotech Atossa Therapeutics has entered into a research collaboration with China-backed Nona Biosciences, aiming to identify next-generation antibody therapies for breast cancer using Nona’s proprietary platform technology. 10 April 2025
Biotechnology
US clinical-stage biotech Imbria Pharmaceuticals, which is focused on cardiometabolic diseases with high unmet need, says it has closed a $57.5 million Seres B financing. 10 April 2025
Pharmaceutical
Pain is good. Or finding non-opioid ways to manage it is good, if Latigo Biotherapeutics’ $150 million March fundraise is anything to go by. 10 April 2025
Biotechnology
US biotech ImmunityBio has secured $75 million through a direct offering with a single institutional investor, according to a statement released Tuesday. 10 April 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze